Quantum Partners invest in Neoprobe
This article was originally published in Clinica
An investment by Quantum Partners, a fund advised by Soros Fund Management, has netted cancer diagnostics company Neoprobe $5.8 million. Quantum purchased 575,000 stock for $10.50 a share. This raises Quantum's stake in Neoprobe to 4.3%. The company says the proceeds will assist in the development of its RIGScan products for treatment of breast, ovarian and prostate cancers, a technology which consists of gamma-detecting instruments, cancer-targeting agents and methods for their use.